Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
H Döhner, EH Estey, S Amadori… - Blood, The Journal …, 2010 - ashpublications.org
In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
JW Vardiman, J Thiele, DA Arber… - Blood, The Journal …, 2009 - ashpublications.org
Recently the World Health Organization (WHO), in collaboration with the European
Association for Haematopathology and the Society for Hematopathology, published a …
Association for Haematopathology and the Society for Hematopathology, published a …
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
U Creutzig, MM van Den Heuvel-Eibrink… - Blood, The Journal …, 2012 - ashpublications.org
Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …
Biological and clinical consequences of NPM1 mutations in AML
Acute myeloid leukemia (AML) is characterized by accumulation of myeloid cells in the bone
marrow because of impaired differentiation and proliferation, resulting in hematopoietic …
marrow because of impaired differentiation and proliferation, resulting in hematopoietic …
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
U Bacher, C Haferlach, W Kern… - Blood, The Journal …, 2008 - ashpublications.org
We characterized the mutational status of the FLT3 tyrosine kinase domain (FLT3-TLD) in
3082 patients with newly diagnosed AML. FLT3-TKD mutations were detected in 147 of …
3082 patients with newly diagnosed AML. FLT3-TKD mutations were detected in 147 of …
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
A Van Rhenen, N Feller, A Kelder, AH Westra… - Clinical cancer …, 2005 - AACR
Purpose: In CD34-positive acute myeloid leukemia (AML), the leukemia-initiating event
originates from the CD34+ CD38− stem cell compartment. Survival of these cells after …
originates from the CD34+ CD38− stem cell compartment. Survival of these cells after …
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group
T Büchner, WE Berdel, C Haferlach… - Journal of Clinical …, 2009 - ascopubs.org
Purpose The purpose of the study was to assess the contribution of age and disease
variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving …
variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving …
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
S Schnittger, TM Kohl, T Haferlach, W Kern… - Blood, 2006 - ashpublications.org
Mutations in codon D816 of the KIT gene represent a recurrent genetic alteration in acute
myeloid leukemia (AML). To clarify the biologic implication of activation loop mutations of the …
myeloid leukemia (AML). To clarify the biologic implication of activation loop mutations of the …
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 …
C Schoch, W Kern, S Schnittger, W Hiddemann… - Leukemia, 2004 - nature.com
The aim of this study was to compare the pattern of karyotype abnormalities of therapy-
related acute myeloid leukemia (t-AML)(n= 93) with de novo AML (n= 1091), and to evaluate …
related acute myeloid leukemia (t-AML)(n= 93) with de novo AML (n= 1091), and to evaluate …
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients …
W Kern, D Voskova, C Schoch, W Hiddemann… - Blood, 2004 - ashpublications.org
Quantification of minimal residual disease (MRD) reveals significant prognostic information
in patients treated for acute myeloid leukemia (AML). The application of multiparameter flow …
in patients treated for acute myeloid leukemia (AML). The application of multiparameter flow …